Evaluation of a Targeted Next-Generation Sequencing Panel for the Non-Invasive Detection of Variants in Circulating DNA of Colorectal Cancer.

Autor: Rodríguez-Casanova A; Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.; Translational Medical Oncology Group (Oncomet), Roche-Chus Joint Unit, Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain., Bao-Caamano A; Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain., Lago-Lestón RM; Translational Medical Oncology Group (Oncomet), Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain., Brozos-Vázquez E; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain., Costa-Fraga N; Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain., Ferreirós-Vidal I; Translational Medical Oncology Group (Oncomet), Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain., Abdulkader I; Department of Pathology, University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain., Vidal-Insua Y; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain., Rivera FV; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain., Candamio Folgar S; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain., López-López R; Translational Medical Oncology Group (Oncomet), Roche-Chus Joint Unit, Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain., Muinelo-Romay L; Translational Medical Oncology Group (Oncomet), Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain., Diaz-Lagares A; Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain.

Publikováno v: Journal of clinical medicine [J Clin Med] 2021 Sep 29; Vol. 10 (19). Date of Electronic Publication: 2021 Sep 29.

Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study.

Autor: Insua YV; Translational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. Yolanda.Vidal.Insua@sergas.es., Cámara J; Arquitecto Macide Hospital, SERGAS Group, Av. Residencia s/n, 15405 Ferrol, Spain. juan.cruz.de.la.camara.gomez@sergas.es., Vázquez EB; Translational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. elenambrozosv@hotmail.com., Fernández A; University Hospital of Ourense, SERGAS Group, Ramon Puga 54, 32005 Ourense, Spain. afm1003@hotmail.com., Rivera FV; Translational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. Francisca.Vazquez.Rivera@sergas.es., Silva MJVV; University Hospital of Vigo, SERGAS Group, Pizarro 22, 36204 Vigo, Spain. maria.jose.villanueva.silva@sergas.es., Barbazán J; Translational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. jorgebarbazan@gmail.com., Muinelo-Romay L; Translational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. lmuirom@gmail.com.; Liquid Biopsy Analysis Unit, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. lmuirom@gmail.com., Folgar SC; Translational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. soniasigueiro@yahoo.es., Abalo A; Translational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. alicia.abalo.pineiro@sergas.es.; Liquid Biopsy Analysis Unit, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. alicia.abalo.pineiro@sergas.es., López-López R; Translational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. Rafael.lopez.lopez@sergas.es., Abal M; Translational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. miguel.abal.posada@sergas.es., Alonso-Alconada L; Translational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n, 15706 Santiago de Compostela, Spain. lorena.alonso.alconada@sergas.es.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2017 Jun 13; Vol. 18 (6). Date of Electronic Publication: 2017 Jun 13.